BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair
Authors
Keywords
-
Journal
ONCOGENE
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-03-13
DOI
10.1038/s41388-021-01735-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer
- (2020) Tina Bagratuni et al. EUROPEAN JOURNAL OF CANCER
- Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
- (2020) Lilie L Lin et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Moving Forward in Cervical Cancer: Enhancing Susceptibility to DNA Repair Inhibition and Damage, an NCI Clinical Trials Planning Meeting Report
- (2020) Matthew M Harkenrider et al. JNCI-Journal of the National Cancer Institute
- Epigenetic Therapies for Cancer
- (2020) Susan E. Bates NEW ENGLAND JOURNAL OF MEDICINE
- First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity
- (2019) Sophie Postel-Vinay et al. EUROPEAN JOURNAL OF CANCER
- Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Zefei Jiang et al. LANCET ONCOLOGY
- Distinctive clinicopathologic characteristics and prognosis for different histologic subtypes of early cervical cancer
- (2019) Lijie Cao et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency
- (2018) Chaoyang Sun et al. CANCER CELL
- Radioresistant Cervical Cancers Are Sensitive to Inhibition of Glycolysis and Redox Metabolism
- (2018) Ramachandran Rashmi et al. CANCER RESEARCH
- Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)
- (2018) Jonathan Welti et al. CLINICAL CANCER RESEARCH
- Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors
- (2018) Jeremy Lewin et al. JOURNAL OF CLINICAL ONCOLOGY
- BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc
- (2018) Ning Li et al. Cell Death & Disease
- BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer
- (2018) Xiangyi Li et al. Cell Reports
- Brd4 inhibition suppresses HPV16 E6 expression and enhances chemoresponse: A potential new target in cervical cancer therapy
- (2018) Olga Rataj et al. INTERNATIONAL JOURNAL OF CANCER
- Targeting histone deacetylase 4/ubiquitin-conjugating enzyme 9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells in mice
- (2017) Chiao-Ling Tsai et al. HEPATOLOGY
- Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies
- (2017) Rahul Aggarwal et al. JOURNAL OF CLINICAL ONCOLOGY
- Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance
- (2017) Sydney M. Shaffer et al. NATURE
- Repression of BET activity sensitizes homologous recombination–proficient cancers to PARP inhibition
- (2017) Lu Yang et al. Science Translational Medicine
- BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer
- (2017) Sergey Karakashev et al. Cell Reports
- A radiosensitizing effect of RAD51 inhibition in glioblastoma stem-like cells
- (2016) Anaïs Balbous et al. BMC CANCER
- Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma – The SHELTER study
- (2016) Michael Bitzer et al. JOURNAL OF HEPATOLOGY
- BRD4 localization to lineage-specific enhancers is associated with a distinct transcription factor repertoire
- (2016) Zeynab Najafova et al. NUCLEIC ACIDS RESEARCH
- Non-targeted radiation effects in vivo: A critical glance of the future in radiobiology
- (2015) Vasiliki I. Hatzi et al. CANCER LETTERS
- Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors
- (2015) Matthew Zibelman et al. INVESTIGATIONAL NEW DRUGS
- Focal Adhesion Kinase and Wnt Signaling Regulate Human Ductal Carcinoma In Situ Stem Cell Activity and Response to Radiotherapy
- (2015) Kathryn E. Williams et al. STEM CELLS
- A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer
- (2014) R M Glasspool et al. BRITISH JOURNAL OF CANCER
- Experimental study on the regulation of erlotinib-induced radiosensitization with an anti-c-MET monoclonal antibody
- (2014) Hong-Qing Zhuang et al. Cancer Cell International
- Chromatin Reader Brd4 Functions in Ig Class Switching as a Repair Complex Adaptor of Nonhomologous End-Joining
- (2014) Andre Stanlie et al. MOLECULAR CELL
- Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance
- (2014) Hariharan Easwaran et al. MOLECULAR CELL
- Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762
- (2013) A. Chaidos et al. BLOOD
- Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma
- (2013) Z. Cheng et al. CLINICAL CANCER RESEARCH
- Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor
- (2013) Denise A. Yardley et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: Potential role of hypoxia
- (2012) Delphine Tamara Marie-Egyptienne et al. CANCER LETTERS
- Cancer Epigenetics: From Mechanism to Therapy
- (2012) Mark A. Dawson et al. CELL
- A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
- (2011) P N Munster et al. BRITISH JOURNAL OF CANCER
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
- (2011) Mark A. Dawson et al. NATURE
- Aberrant Epigenetic Landscape in Cancer: How Cellular Identity Goes Awry
- (2010) María Berdasco et al. DEVELOPMENTAL CELL
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started